Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Pulmonology

Long-Term Monitoring and Daily Management

At a Glance

Long-term NSIP care focuses on trends in symptoms, FVC, DLCO, walking ability, and oxygen levels rather than one test. Regular follow-up, pulmonary rehabilitation, prescribed oxygen, and evaluation for pulmonary hypertension can help protect function and quality of life.

Living with Non-Specific Interstitial Pneumonia (NSIP) requires moving from a mindset of “diagnosis” to one of “management.” Because NSIP can be stable for years or progress slowly, your medical team will use a variety of tools to track the “trend” of your lung health rather than looking at any single test result in isolation [1][2].

Your Monitoring Calendar

While every patient is different, a practical monitoring schedule often involves a comprehensive review every 3 to 6 months if your disease is active or your treatment is changing [2]. Once you are stable, these check-ups may move to every 6 to 12 months [1].

During these visits, you will typically undergo:

  • Spirometry (FVC): This measures Forced Vital Capacity, or how much air you can blow out after a deep breath. Current progressive pulmonary fibrosis (PPF) frameworks generally evaluate change over about a year. A relative FVC decline of at least 5% predicted when accompanied by worsening symptoms or radiologic progression can signal clinically important change [3][4].
  • Diffusing Capacity (DLCO): This test measures how well oxygen moves from your lungs into your blood. A decline of at least 10% predicted can be meaningful, but DLCO is also affected by anemia, emphysema, pulmonary vascular disease, and test quality, so it is interpreted as part of the broader picture [5][6].
  • Six-Minute Walk Test (6MWT): This measures how far you can walk on a flat surface in six minutes. It is a “real-world” test that helps your doctors see how your lungs and heart handle exertion [1][7].

If you experience worsening breathlessness, do not automatically assume your lung scarring has progressed. Other common non-NSIP reasons include deconditioning, anemia, cardiac disease, asthma or COPD exacerbations, or infection.

Note: While you will have regular breathing tests, you will likely not have a CT scan at every visit. Repeat HRCT scans are usually reserved for times when your symptoms or breathing tests show a significant change [3].

Monitoring for Pulmonary Hypertension

In some cases of NSIP, the blood pressure in the lungs can rise, a condition called Pulmonary Hypertension (PH) [8]. This can happen because of hypoxic vasoconstriction, vascular remodeling, left-heart disease, or thromboembolic disease [9].

Your doctor will look for “clues” that your heart is working too hard, such as:

  • Promptly report any exertional syncope (fainting), severe chest pain, or rapidly worsening ankle swelling [8].
  • Shortness of breath that seems disproportionate to your lung scans [8].
  • A rapid drop in your DLCO numbers even if your FVC remains stable [10].

If PH is suspected, you may be referred for an echocardiogram (an ultrasound of the heart) or a blood test called BNP as screening tools [9][11]. Right-heart catheterization is the diagnostic reference standard to confirm it.

Daily Management: Staying Active

The goal of daily management is to maximize your quality of life and keep your body as strong as possible.

Pulmonary Rehabilitation (PR)

Pulmonary rehab is one of the most effective “non-drug” treatments for NSIP [12]. It is a supervised program that combines:

  • Exercise Training: Aerobic and strength exercises tailored to your current ability [13].
  • Education: Learning techniques for managing shortness of breath and energy conservation [14].
  • Support: Connecting with others who understand the challenges of living with a chronic lung condition [15].

Studies show that patients with NSIP—including the fibrotic subtype—often see significant improvements in their walking distance and overall energy levels after completing a program [15][16].

Oxygen Therapy

If your blood oxygen levels drop significantly during sleep, at rest, or during exercise, your doctor may prescribe supplemental oxygen to an individualized target [17].

  • Ambulatory Oxygen: This is used during activity to help you stay mobile and reduce the strain on your heart and lungs [18].
  • Oxygen Safety: You absolutely must not smoke or use open flames near oxygen. It is a severe fire hazard. Do not change your flow rate based solely on a home pulse oximeter without medical advice.

Protecting Your Health

If you smoke, the most important thing you can do for your overall lung and cardiovascular health is to stop immediately [17]. Create a practical monitoring log for yourself that records symptoms, activity, oxygen use, medication side effects, and questions for your team.

Common questions in this guide

How often should I have breathing tests for NSIP?
If NSIP is active or your treatment is changing, clinicians often review you every 3 to 6 months. Once the condition is stable, visits may be spaced to every 6 to 12 months, depending on your symptoms, test trends, and treatment plan.
What do FVC and DLCO show in NSIP?
FVC measures how much air you can breathe out after taking a deep breath. DLCO estimates how well oxygen moves from your lungs into your blood, and doctors interpret both results alongside symptoms, imaging, other health conditions, and test quality.
Does worsening breathlessness mean that NSIP has progressed?
Not always. Deconditioning, anemia, heart disease, asthma or COPD flare-ups, infections, and other problems can cause breathlessness, so your care team may compare your symptoms with breathing tests and imaging.
When might I need another CT scan for NSIP?
A high-resolution CT scan is not usually repeated at every visit. Your clinician may recommend one if your symptoms or breathing tests change significantly or if a new concern needs investigation.
What symptoms could suggest pulmonary hypertension with NSIP?
Fainting during exertion, severe chest pain, rapidly worsening ankle swelling, or breathlessness that seems out of proportion to your lung findings should be reported promptly. A rapid fall in DLCO despite stable FVC may also lead your clinician to investigate, often with heart ultrasound or blood testing and, when needed, right-heart catheterization.
Can pulmonary rehabilitation help people with NSIP?
Pulmonary rehabilitation combines individualized aerobic and strength exercises with education about breathing and conserving energy. It can improve walking distance and energy levels, including for people with fibrotic NSIP.
How can I use supplemental oxygen safely?
Use oxygen exactly as prescribed, and never smoke or use open flames near it because oxygen creates a serious fire hazard. Do not change the flow rate based only on a home pulse oximeter without medical advice.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our specific monitoring schedule for 'breathing tests' (FVC and DLCO) while I am on this current treatment?
  2. 2.Is my level of shortness of breath 'proportionate' to the amount of scarring seen on my scans, or should we screen for pulmonary hypertension or other issues?
  3. 3.Can you refer me to a pulmonary rehabilitation program that is experienced in working with interstitial lung disease patients?
  4. 4.How do we decide when it is time for a follow-up HRCT scan versus relying on my breathing tests?
  5. 5.If my disease progresses, at what point should we discuss a referral for a lung transplant evaluation or palliative care consultation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Functional, radiological and survival outcomes in rheumatoid arthritis-associated interstitial lung disease: 24-month results from the BERTHA prospective cohort.

    Kawano-Dourado L, Bonfiglioli K, Ribeiro ACM, et al.

    BMJ open respiratory research 2026; (13(1)) doi:10.1136/bmjresp-2025-003973.

    PMID: 41760357
  2. 2

    Predictors of Progressive Fibrosing Interstitial Lung Diseases and Survival in Fibrosing Interstitial Lung Disease-Related Usual Interstitial Pneumonia.

    Fu H, Li X, Shi H, et al.

    Medicina (Kaunas, Lithuania) 2026; (62(1)) doi:10.3390/medicina62010206.

    PMID: 41597492
  3. 3

    Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.

    Maher TM, Brown KK, Kreuter M, et al.

    The European respiratory journal 2022; (59(2)) doi:10.1183/13993003.04587-2020.

    PMID: 34210788
  4. 4

    Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.

    Fernández-Díaz C, Castañeda S, Melero-González RB, et al.

    Rheumatology (Oxford, England) 2020; (59(12)):3906-3916 doi:10.1093/rheumatology/keaa621.

    PMID: 33068439
  5. 5

    Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.

    Yıldırım F, Türk M, Bitik B, et al.

    The Kaohsiung journal of medical sciences 2019; (35(6)):365-372 doi:10.1002/kjm2.12066.

    PMID: 30913371
  6. 6

    Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases.

    Ciancio N, Pavone M, Torrisi SE, et al.

    Multidisciplinary respiratory medicine 2019; (14()):17 doi:10.1186/s40248-019-0179-2.

    PMID: 31114679
  7. 7

    Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline.

    Nagy A, Nagy T, Kolonics-Farkas AM, et al.

    Frontiers in pharmacology 2021; (12()):778649 doi:10.3389/fphar.2021.778649.

    PMID: 35002713
  8. 8

    Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study.

    Rahaghi FF, Kolaitis NA, Adegunsoye A, et al.

    Chest 2022; (162(1)):145-155 doi:10.1016/j.chest.2022.02.012.

    PMID: 35176276
  9. 9

    The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment.

    King CS, Shlobin OA

    Chest 2020; (158(4)):1651-1664 doi:10.1016/j.chest.2020.04.046.

    PMID: 32387520
  10. 10

    Navigating the Complexity of PH-ILD: From Molecular Mechanisms to Integrated Clinical Evaluation.

    Vasarmidi E, Calaras D, Kourouni I, et al.

    International journal of molecular sciences 2026; (27(15)) doi:10.3390/ijms27157055.

    PMID: 42589704
  11. 11

    Pulmonary Hypertension in Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

    Ang HL, Schulte M, Chan RK, et al.

    Chest 2024; (166(4)):778-792 doi:10.1016/j.chest.2024.04.025.

    PMID: 38821182
  12. 12

    Pulmonary rehabilitation for interstitial lung disease.

    Dowman L, Hill CJ, May A, Holland AE

    The Cochrane database of systematic reviews 2021; (2()):CD006322 doi:10.1002/14651858.CD006322.pub4.

    PMID: 34559419
  13. 13

    Principles of rehabilitation and reactivation: interstitial lung disease, sarcoidosis and rheumatoid disease with respiratory involvement.

    Holland AE, Dowman LM, Hill CJ

    Respiration; international review of thoracic diseases 2015; (89(2)):89-99 doi:10.1159/000370126.

    PMID: 25633076
  14. 14

    Respiratory Impairment, Limited Activity, and Pulmonary Rehabilitation in Patients with Interstitial Lung Disease.

    Kozu R, Shingai K, Hanada M, et al.

    Physical therapy research 2021; (24(1)):9-16 doi:10.1298/ptr.R0012.

    PMID: 33981523
  15. 15

    Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias.

    Wallaert B, Duthoit L, Drumez E, et al.

    ERJ open research 2019; (5(2)) doi:10.1183/23120541.00045-2019.

    PMID: 30972352
  16. 16

    Does the severity of interstitial lung disease affect the gains from pulmonary rehabilitation?

    Deniz S, Şahin H, Yalnız E

    The clinical respiratory journal 2018; (12(6)):2141-2150 doi:10.1111/crj.12785.

    PMID: 29498799
  17. 17

    Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline.

    Jacobs SS, Krishnan JA, Lederer DJ, et al.

    American journal of respiratory and critical care medicine 2020; (202(10)):e121-e141 doi:10.1164/rccm.202009-3608ST.

    PMID: 33185464
  18. 18

    Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

    Visca D, Mori L, Tsipouri V, et al.

    The Lancet. Respiratory medicine 2018; (6(10)):759-770 doi:10.1016/S2213-2600(18)30289-3.

    PMID: 30170904

This page is for informational purposes only and does not constitute medical advice about your NSIP. Discuss changes in symptoms, oxygen use, exercise, or follow-up testing with your pulmonologist or care team.

Get notified when new evidence is published on Non-specific interstitial pneumonia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.